Login to Your Account

Gene therapy firm Vivet adds $41M in series A for gene therapy work

By Nuala Moran
Staff Writer

Thursday, May 4, 2017

LONDON – Vivet Therapeutics has raised $41 million in a series A round to fund development of liver-targeted gene therapies for treating inherited metabolic disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription